Skip to content
DataLookout
Menu

NCT07938697

Development and Testing of a Brief Tool to Assess Breakthrough Cancer Pain in Taiwan

StatusRecruiting
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Item-Level Content Validity Index of the BCPA
Timeframe: At each Delphi round during an assessment period of approximately one month (maximum of four rounds).
Scale-Level Content Validity Indices of the BCPA
Timeframe: At completion of the Delphi content-validation process, approximately one month after the first round (maximum of four rounds).
Inter-Rater Agreement for Categorical BCPA Items
Timeframe: Day 1; the two independent assessments are completed within three hours.
Inter-Rater Consistency for Continuous BCPA Items
Timeframe: Day 1; the two independent assessments are completed within three hours.

Secondary (3)

Percentage of Patients With Meaningful Pain Relief Within or at 15 Minutes After Painkyl Administration
Change in the Percentage of Patients Reporting Meaningful Pain Relief Within 15 Minutes From Pretreatment to Post-treatment
Change From Pretreatment to Post-treatment in Usual Breakthrough Pain Intensity

Arms and interventions

BCPA-guided assessment and Painkyl treatmentExperimental

In the clinical application stage, patients receiving short-acting opioids other than Painkyl undergo BCPA assessment. Those with unsatisfactory breakthrough pain control and/or requiring a change in medication administration route receive individually titrated Painkyl and a follow-up BCPA assessment. Patients with satisfactory pain relief at the initial assessment undergo no further study procedures. There is no comparator arm. The preceding tool-development stage includes a separate group of 30 patients. Two medical staff members separately interview each patient within three hours on the same day and independently record the answers for inter-rater reliability testing.

Drugs: Fentanyl buccal soluble film

Sites

4 sites in 1 country